BMC Neurology, 2021 Background Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications
Dulanji K. Kuruppu +5 more
doaj +1 more source
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months [PDF]
, 2021 Erenumab; Migranya; Anticossos monoclonalsErenumab; Migraña; Anticuerpos monoclonicosErenumab; Migraine; Monoclonal antibodiesBackground In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication ...
Alpuente, Alicia +5 more
core +2 more sources
Cephalalgia Reports, 2020 Objective: This study was designed to assess the efficacy and safety of galcanezumab in comparison with placebo for the prevention of migraine in Japanese patients with episodic migraine. Methods: In this double-blind, placebo-controlled study, which was
Fumihiko Sakai +2 more
doaj +1 more source
A Comparison of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard Migraine Prophylaxis in Those with Episodic Migraines [PDF]
, 2023 Migraines are debilitating and a frequent reason for primary care visits. Migraines interfere with an individual’s work, school, and daily life.
Harms, Alexie
core +4 more sources
Frontiers in Pharmacology, 2017 Background: Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment.
David Monteith +9 more
doaj +1 more source
Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study [PDF]
, 2023 Background: About 15% to one third of migraineurs experience aura symptoms. Aura is a reversible focal neurological phenomenon involving visual, sensory, speech, and motor symptoms that usually precede migraine pain.
Braca, Simone +5 more
core +1 more source
SHOULD ANTI-CGRP MONOCLONAL ANTIBODIES ALWAYS BE THE DRUG OF FIRST CHOICE FOR MIGRAINE PROPHYLAXIS IN BRAZIL? - A PHARMACOECONOMIC STUDY [PDF]
Efficacy (success of therapy under ideal conditions), efficiency (the relationship between the costs and outcomes of a specific intervention), and effectiveness (the balance between efficacy and efficiency in clinical practice) are measures used to ...
Bordini, Carlos Alberto +2 more
core +5 more sources
The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis [PDF]
, 2023 OBJECTIVE: While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety and efficacy of these drugs.
Deligianni, Christina I. +10 more
core +3 more sources
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
BMC Neurology, 2018 Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine ...
Angelo Camporeale +6 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Background Clinical trials have demonstrated galcanezumab as safe and effective in migraine prevention. However, real-life data are still lacking and overlook the impact of galcanezumab on those different migraine facets strongly contributing to migraine
Marcello Silvestro +7 more
doaj +1 more source